In this episode of MD Newsline, Dr. Leena Padhye, allergist and immunologist, explores the evolving landscape of food allergy diagnosis and treatment. She discusses the growing role of biologic therapies such as omalizumab (Xolair), the practical realities of oral immunotherapy (OIT), and emerging approaches that may transform food allergy management in the future.

Dr. Padhye highlights key considerations for patient selection, the importance of recognizing anaphylaxis early, and the critical role of epinephrine as a lifesaving intervention. She also shares insights on multidisciplinary care, food allergy advocacy, and how frontline clinicians can improve outcomes for patients, even when access to allergy specialists is limited.

The Expanding Role of Biologic Therapy in Food Allergy

Dr. Padhye discusses omalizumab (Xolair), the first FDA-approved biologic therapy for food allergy. She explains how the treatment is used across a wide age range, including young children, and reviews practical considerations regarding patient eligibility, insurance approval, and treatment access.

Oral Immunotherapy: Benefits and Patient Selection

Not every patient is an ideal candidate for oral immunotherapy. Dr. Padhye explains how allergists evaluate factors such as age, allergy severity, IgE levels, skin testing results, and overall risk before recommending OIT. She also discusses the importance of individualized treatment planning.

Emerging Therapies and Future Directions

The conversation explores the current status of epicutaneous and sublingual immunotherapy, along with future treatment possibilities. Dr. Padhye shares her optimism that advances in allergy research may eventually lead to more convenient and potentially curative therapies.

Anaphylaxis Management and the Importance of Epinephrine

A major theme of the discussion is the need for rapid recognition and treatment of anaphylaxis. Dr. Padhye emphasizes that delaying epinephrine administration remains one of the most significant risk factors for severe allergic reactions and encourages clinicians to reinforce this message with patients and caregivers.

Food Allergy and Asthma: A High-Risk Combination

Dr. Padhye explains why uncontrolled asthma increases the risk of severe anaphylaxis and discusses the importance of optimizing asthma management in food-allergic patients. She also highlights opportunities for collaboration between allergists, pulmonologists, and primary care providers.

Advocacy, Education, and Community Safety

Beyond prescribing epinephrine, Dr. Padhye encourages clinicians to support policies that improve public access to emergency allergy treatment in schools, camps, restaurants, and other community settings. She discusses the growing movement to stock epinephrine in public spaces and improve allergy awareness.

Improving Care in Areas with Limited Specialist Access

For clinicians practicing in communities without immediate access to allergy specialists, Dr. Padhye shares practical steps that can improve patient safety, including the use of food allergy action plans, patient education materials, and timely epinephrine prescriptions.

Key Takeaway

Dr. Padhye emphasizes that food allergy care is rapidly evolving, with biologic therapies and immunotherapy creating new opportunities to improve patient outcomes. Early recognition of anaphylaxis, prompt use of epinephrine, multidisciplinary collaboration, and patient education remain essential components of effective food allergy management.

Website: https://mdnewsline.com/

Newsletter: https://mdnewsline.com/subscribe/